SFDA Approval Granted for Dehaier Medical Ltd. (DHRM) DHR-CPAP-C5 Device for Treating Sleep Apnea

Dehaier Medical Systems announced that it has obtained State Food and Drug Administration approval for DHR-CPAP-C5, one of the company’s primary proprietary homecare medical devices. The validity period for the SFDA approval is four years.

Continuous positive airway pressure (CPAP) has become the first-line treatment for obstructive sleep apnea syndrome (OSAS), as well as for some forms of central sleep apnea. CPAP works by creating a pneumatic splint for the upper airway. Pressurized air is sent through air tubing and a mask (generally a nose mask) and through the nose to the upper airway by means of a flow generator. This pressurized air keeps the upper airway’s soft tissues from narrowing and collapsing. For proper CPAP treatment, a patient can set high enough flow generator pressures to avoid apneas and hypopneas during all sleep stages and in all sleep positions. The SFDA approval indicates that DHR-CPAP-C5 has met all national health and safety standards, and it will soon be launched in China.

An up-and-coming leader in developing, assembling, marketing, and selling medical devices and homecare medical products in China, Dehaier is focused on offering all-in-one solutions for diagnosing, treating, and assessing OSAS. The company’s DHR-998, used for diagnosis and treatment evaluation, has emerged in the international market after CE Mark approval was received in 2011. The company will continue strengthening its domestic marketing efforts while exploring new business models and strategic partnerships.

One of Dehaier’s critical business strategies involves developing and expanding its market share of homecare medical equipment, based on a belief in the growth potential of the Chinese homecare medical market. Through considerable efforts regarding R&D, product upgrades, product diversification, and patent expansion, the company is positioned to both educate Chinese consumers about the concept of homecare and to serve the burgeoning demand for homecare medical equipment.

The receipt of SFDA approval for DHR-CPAP-C5 is an important step toward providing a complete solution for fighting sleep disorders.

Dehaier is a leading provider of medical products in China, including respiratory and oxygen homecare medical products. The company is engaged in developing and assembling its own branded medical devices and homecare medical products from third-party components. Dehaier additionally distributes products designed and manufactured by other companies, including IMD in Italy, Welch Allyn in the U.S., HEYER in Germany, Temisco in the U.K., eVent Medical in the U.S., and JMS in Japan. The company bases its technology on six patents, nine software copyrights, and proprietary technology.

For more information, visit the company’s Web site at www.dehaier.com.cn

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html